EU/3/11/944: Orphan designation for the treatment of mercury toxicity

N,N'-bis(2-mercaptoethyl)isophthalamide (emeramide)


On 11 January 2012, orphan designation (EU/3/11/944) was granted by the European Commission to CTI Science Limited, Ireland, for N,N'-bis(2-mercaptoethyl)isophthalamide for the treatment of mercury toxicity.

In July 2015, CTI Science Limited changed name to NBMI Science Limited.

This medicine is now known as emeramide.

Key facts

Active substance
N,N'-bis(2-mercaptoethyl)isophthalamide (emeramide)
Intended use
Treatment of mercury toxicity
Orphan designation status
EU designation number
Date of designation
NBMI Science Limited
Trinity House
Charleston Road
Dublin 6
Tel. +353 1 237 3700

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating